Plenary Speaker

Richard Bonneau, PhD

VP ML for Drug Discovery, gRED Computational Sciences @ Genentech

AI in drug discovery - Title TBA

Tom Forest, PhD

Distinguished Scientist @ Merck

Comparison of Supervised and Unsupervised Machine Learning Scoring of Histology Images

Magali Guffroy, PhD

Global Head of Pathology, Preclinical Safety @ AbbVie

unique toxicities associated with ADC's - Title TBA

Fangyao Hu, PhD

Tech Lead Manager Digital Pathology | Safety Assessment @ Genentech

computational AI - Title TBA

Pia Kasperkovitz, PhD

Senior Director Toxicology @ Bright Peak Therapeutics

Case study: Regulatory Interactions and Path To IND For a Novel Antibody-protein Conjugate

Mahua Roy, PhD

Associate Director, Translational PKPD ; ADC Clinical Pharmacology Quantitative Pharmacology @ AstraZeneca

(Tentative Title) Recent Developments or Learnings: PK/PD Modeling, TI Prediction and Translatability Challenges

Jacintha Shenton, PhD

Associate Vice President, Global Head Portfolio, Pharmacology, & Data Sciences (PPDS) in Translational Safety & Bioanalytical Sciences @ Amgen

Use of NAMS in nonclinical safety assessment - Title TBA

Jessica D. Sims, PhD, DABT

Principal Scientist-Toxicology @ Genentech

Molecular glue degraders - Title TBA

Rami Skaliter, PhD

Chief Executive Officer @ Cell Cure Neurosciences Ltd.

OpRegen and OPC1 programs - Title TBA

Kevin Snyder, PhD

Associate Director of Nonclinical Informatics @ FDA

Regulatory expertise on the use of virtual controls in toxicity studies and the use of NAMs in the toxicology package to support clinical development - Title TBA

Xiaoting Wang, PhD, DABT

Director, Translational Safety and Bioanalytical Sciences @ Amgen

Global Off-target Profiling of Targeted Protein Degraders With a Cell-based Proteomics Platform

Jillian Wendel, PhD

Study Director and Neurobehavioral Subject Matter Expert @ Labcorp

Virtual controls - Title TBA